(Q46546957)

23 December 2017

title

Effect of subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation rates (English)

1 reference

23 December 2017

main subject

Mycobacterium fortuitum

object named as

Mycobacterium fortuitum

1 reference

based on heuristic

inferred from title

Mycobacterium fortuitum

0 references

author

Timothy D. McHugh

5

1 reference

23 December 2017

author name string

Stephen H Gillespie

1

1 reference

23 December 2017

Shreya Basu

2

1 reference

23 December 2017

Anne L Dickens

3

1 reference

23 December 2017

Denise M O'Sullivan

4

1 reference

23 December 2017

language of work or name

English

0 references

publication date

14 June 2005

1 reference

23 December 2017

Journal of Antimicrobial Chemotherapy

published in

1 reference

23 December 2017

volume

56

1 reference

23 December 2017

page(s)

344-348

1 reference

23 December 2017

issue

2

1 reference

23 December 2017

Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI191

Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI191

A comparison of the bactericidal activity of quinolone antibiotics in a Mycobacterium fortuitum model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI191

Activity of moxifloxacin against mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI191

Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI191

The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI191

Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI191

Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI191

DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI191

DNA repair in Mycobacterium tuberculosis. What have we learnt from the genome sequence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI191

Error‐prone DNA polymerase IV is controlled by the stress‐response sigma factor, RpoS, in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI191

Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI191

Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatmen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI191

Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI191

Determining mutation rates in bacterial populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI191

Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI191

Diagnosis and Treatment of Disease Caused by Nontuberculous Mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI191

Structure-activity relationships of the quinolone antibacterials against mycobacteria: effect of structural changes at N-1 and C-7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI191

Effect of lipophilicity at N-1 on activity of fluoroquinolones against mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI191

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI191

High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI191

High frequency of mutator strains among human uropathogenic Escherichia coli isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI191

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI191

Highly Variable Mutation Rates in Commensal and Pathogenic Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI191

Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI191

21 January 2018

Identifiers

DOI

10.1093/JAC/DKI191

1 reference

23 December 2017

PubMed ID

15956099

1 reference

23 December 2017